Hamilton Wealth LLC Has $7.82 Million Holdings in Merck & Co., Inc. $MRK

Hamilton Wealth LLC lessened its position in shares of Merck & Co., Inc. (NYSE:MRK) by 44.2% in the first quarter, HoldingsChannel reports. The fund owned 65,034 shares of the company’s stock after selling 51,512 shares during the period. Merck & Co., Inc. accounts for approximately 1.5% of Hamilton Wealth LLC’s investment portfolio, making the stock its 19th largest holding. Hamilton Wealth LLC’s holdings in Merck & Co., Inc. were worth $7,823,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in MRK. Chesapeake Wealth Management lifted its holdings in Merck & Co., Inc. by 0.6% during the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after purchasing an additional 87 shares during the last quarter. South Plains Financial Inc. grew its holdings in Merck & Co., Inc. by 0.6% in the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock valued at $1,635,000 after buying an additional 89 shares in the last quarter. Syverson Strege & Co grew its holdings in Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock valued at $436,000 after buying an additional 90 shares in the last quarter. Nations Financial Group Inc. IA ADV increased its position in Merck & Co., Inc. by 0.4% during the 1st quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock worth $2,819,000 after buying an additional 91 shares during the period. Finally, Westside Investment Management Inc. increased its position in Merck & Co., Inc. by 3.1% during the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock worth $331,000 after buying an additional 93 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MRK. Guggenheim boosted their target price on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. CICC Research began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective for the company. Scotiabank boosted their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $134.50.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $130.49 on Monday. The stock has a market capitalization of $322.28 billion, a PE ratio of 36.76, a P/E/G ratio of 5.17 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The business has a fifty day moving average price of $123.17 and a two-hundred day moving average price of $118.52. Merck & Co., Inc. has a fifty-two week low of $77.53 and a fifty-two week high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.22 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 95.77%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s launch of subcutaneous Keytruda, known as Qlex, and other lifecycle extensions could preserve the drug’s commercial momentum and support exclusivity through 2039. Recent regulatory approvals, pipeline progress and the acquisitions of Terns and Cidara also broaden the company’s oncology and virology prospects. Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
• Positive Sentiment: Analyst estimates have improved, including Erste Group’s modest increase in its FY2027 EPS forecast to $9.54 from $9.52. Barclays has also forecast strong potential appreciation for MRK, reinforcing the constructive sentiment around the shares. Barclays Forecasts Strong Price Appreciation for Merck & Co., Inc. Stock
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend provides ongoing income support, with a reported annualized yield of about 2.6%.
• Neutral Sentiment: MRK is scheduled to release second-quarter 2026 results before the market opens on August 4. Consensus calls for approximately $16.33 billion in sales and a loss of $0.26 per share, with acquisition costs likely affecting reported earnings. Investors will watch Keytruda demand, Gardasil performance and management’s outlook. Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
• Neutral Sentiment: Merck and Wellcome’s Hilleman Laboratories are preparing an experimental Ebola vaccine for clinical trials. The initiative supports Merck’s public-health profile but is unlikely to materially affect near-term financial results. Merck, Wellcome Partner With Global Health Group to Make Ebola Vaccine for Clinical Trials
• Negative Sentiment: After a roughly 17% rally since its latest quarterly results, MRK may already reflect much of the favorable Keytruda and pipeline news. Analysts characterize its longer-term valuation as justified rather than clearly inexpensive, while Gardasil weakness and the approaching earnings event remain risks. Merck Stock Looks Cheap on Cash Flow but Fair on Earnings

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.